NIH IMPROVE Act

119th Congress Introduced by Brian Fitzpatrick and 2 co-sponsors

Summary of H.R. 6238: The IMPROVE Initiative Act Purpose and IntentThis bill, titled the "IMPROVE Initiative Act," seeks to establish a new program called the IMPROVE (Innovations

Introduced in House

Purpose and Intent

This bill, titled the "IMPROVE Initiative Act," seeks to establish a new program called the IMPROVE (Innovations in Medical Progress and Research Expansion) Initiative within the National Institutes of Health (NIH). The primary goal of the IMPROVE Initiative is to accelerate the development and implementation of innovative medical technologies and treatments, with a focus on areas of unmet clinical need.

Key Provisions

The key provisions of the bill include:

Establishment of the IMPROVE Initiative: The bill directs the NIH to create the IMPROVE Initiative, a cross-cutting program that will coordinate and support research, development, and implementation of novel medical technologies and therapies.

Focus Areas: The Initiative will target areas such as digital health, personalized medicine, regenerative medicine, and other emerging fields with significant potential to improve patient outcomes and transform healthcare.

Funding and Partnerships: The bill authorizes $500 million in annual appropriations to the IMPROVE Initiative. The program will also be empowered to enter into partnerships with private companies, academic institutions, and other stakeholders to leverage additional resources and expertise.

Streamlined Approval Processes: The Initiative will work to develop expedited regulatory review and approval pathways for qualified innovative medical products, in coordination with the FDA, to bring new technologies to patients faster.

Commercialization Support: The program will provide funding, mentoring, and other resources to support the successful commercialization of technologies developed through the Initiative.

Affected Stakeholders

The IMPROVE Initiative is expected to have a broad impact on various stakeholders in the healthcare ecosystem, including:

Patients: Access to innovative, potentially life-changing medical technologies and treatments

Healthcare Providers: Adoption of new tools and therapies to improve patient care

Researchers and Innovators: Increased funding and support for developing novel solutions

Medical Technology Companies: Opportunities for accelerated product development and commercialization

Regulators (FDA): Collaboration on streamlining approval processes for qualified innovations

Timeline and Procedural Aspects

The bill was introduced in the U.S. House of Representatives on November 20, 2025 and is currently in the early stages of the legislative process. If enacted, the IMPROVE Initiative would be established within 6 months of the bill's passage, with the initial funding and programmatic activities commencing in the following fiscal year.